Exact Mass: 427.1591

Exact Mass Matches: 427.1591

Found 61 metabolites which its exact mass value is equals to given mass value 427.1591, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Moricizine

[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester

C22H25N3O4S (427.1566)


Moricizine is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent used primarily for ventricular rhythm disturbances. [PubChem]Moricizine works by inhibiting the rapid inward sodium current across myocardial cell membranes. D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Pemetrexed

(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate

C20H21N5O6 (427.1492)


Pemetrexed is only found in individuals that have used or taken this drug. It is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

   

(1-(2-(Methylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate

(1-(2-(Methylsulphonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylic acid

C19H26FN3O5S (427.1577)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   

[3H]Pemetrexed

2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate

C20H21N5O6 (427.1492)


   
   

(13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine

(13S,14R)-13-O-acetyl-1-hydroxy-N-methylcanadine

C23H25NO7 (427.1631)


   
   

(7R)-8t-acetoxy-6,7-dimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-(7rN)-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinolin]-6t-ol|Raddeanidin|Raddeanidine

(7R)-8t-acetoxy-6,7-dimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-(7rN)-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinolin]-6t-ol|Raddeanidin|Raddeanidine

C23H25NO7 (427.1631)


   
   
   
   

Pemetrexed

Pemetrexed disodium

C20H21N5O6 (427.1492)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BA - Folic acid analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C471 - Enzyme Inhibitor > C2021 - Thymidylate Synthase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents

   
   

2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate

2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate

C16H29NO12 (427.169)


   

Flavoxate hydrochloride

Flavoxate hydrochloride

C24H26ClNO4 (427.155)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D000089162 - Genitourinary Agents > D064804 - Urological Agents Flavoxate hydrochloride is a potent and competitive phosphodiesterase (PDE) inhibitor. Flavoxate hydrochloride is an antispasmodic agent and muscarinic mAChR antagonist. Flavoxate hydrochloride shows moderate calcium antagonistic activity and local anesthetic effect. Flavoxate hydrochloride can be used for the research of overactive bladder (OAB) and lower urinary tract infections[1].

   

Fmoc-DL-7-azatryptophan

Fmoc-DL-7-azatryptophan

C25H21N3O4 (427.1532)


   

3-[3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]propyl 2-methylprop-2-enoate

3-[3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]propyl 2-methylprop-2-enoate

C23H26ClN3O3 (427.1663)


   

3-Indoxyl Phosphate, Di-p-Toluidinium Salt

3-Indoxyl Phosphate, Di-p-Toluidinium Salt

C22H26N3O4P (427.1661)


   
   

Fmoc-L-7-AzaTrp-OH

Fmoc-L-7-AzaTrp-OH

C25H21N3O4 (427.1532)


   

4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinecarboxylic acid 2-(2-hydroxyethoxy)ethyl ester

4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinecarboxylic acid 2-(2-hydroxyethoxy)ethyl ester

C22H25N3O4S (427.1566)


   
   

(3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide

(3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide

C19H29N3O4S2 (427.1599)


   
   

N-(2-carbamoylphenyl)-2-(2,5-dimethoxyphenyl)quinoline-4-carboxamide

N-(2-carbamoylphenyl)-2-(2,5-dimethoxyphenyl)quinoline-4-carboxamide

C25H21N3O4 (427.1532)


   

Magnocurarine trifluoroacetate, rac-

Magnocurarine trifluoroacetate, rac-

C21H24F3NO5 (427.1606)


A natural product found in Gnetum montanum.

   

1,4-Dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione

1,4-Dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione

C22H25N3O4S (427.1566)


   

N-(2-furanylmethyl)-N-[(7-methyl-4-tetrazolo[1,5-a]quinolinyl)methyl]-2-phenoxyacetamide

N-(2-furanylmethyl)-N-[(7-methyl-4-tetrazolo[1,5-a]quinolinyl)methyl]-2-phenoxyacetamide

C24H21N5O3 (427.1644)


   

N,N-dimethyl-4-[[4-(5-methyl-1-benzotriazolyl)-1-piperidinyl]sulfonyl]benzamide

N,N-dimethyl-4-[[4-(5-methyl-1-benzotriazolyl)-1-piperidinyl]sulfonyl]benzamide

C21H25N5O3S (427.1678)


   
   
   
   

3-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

3-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

3-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

3-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

3-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

[(1S)-7-methoxy-1-(3-methylphenyl)sulfonyl-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1S)-7-methoxy-1-(3-methylphenyl)sulfonyl-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol

C22H25N3O4S (427.1566)


   

3-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

3-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   

3-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

3-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide

C19H26FN3O5S (427.1577)


   
   
   
   
   
   
   
   
   

2-Amino-3-[(3-butanoyloxy-2-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

2-Amino-3-[(3-butanoyloxy-2-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

C16H30NO10P (427.1607)


   

2-Amino-3-[2,3-di(pentanoyloxy)propoxy-hydroxyphosphoryl]oxypropanoic acid

2-Amino-3-[2,3-di(pentanoyloxy)propoxy-hydroxyphosphoryl]oxypropanoic acid

C16H30NO10P (427.1607)


   

2-Amino-3-[(2-heptanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

2-Amino-3-[(2-heptanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid

C16H30NO10P (427.1607)


   

3-[(3-Acetyloxy-2-octanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid

3-[(3-Acetyloxy-2-octanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid

C16H30NO10P (427.1607)


   

MORICIZINE

MORICIZINE

C22H25N3O4S (427.1566)


D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   
   
   

3-hydroxy-3-[(1r)-1-{6-hydroxy-5-[(methylsulfanyl)methyl]-3-(2-oxocyclopent-3-en-1-ylidene)-4,5-dihydro-2h-pyrazin-2-yl}ethyl]-1-methylindol-2-one

3-hydroxy-3-[(1r)-1-{6-hydroxy-5-[(methylsulfanyl)methyl]-3-(2-oxocyclopent-3-en-1-ylidene)-4,5-dihydro-2h-pyrazin-2-yl}ethyl]-1-methylindol-2-one

C22H25N3O4S (427.1566)


   

(2s)-2-{[(2s,3r)-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1,3-dihydroxybutylidene]amino}-5-(n-hydroxyacetamido)pentanoic acid

(2s)-2-{[(2s,3r)-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1,3-dihydroxybutylidene]amino}-5-(n-hydroxyacetamido)pentanoic acid

C18H25N3O9 (427.1591)


   

7-hydroxy-2-(2-hydroxyethyl)-6-(3-methylbut-2-en-1-yl)-3-oxo-1h-isoindol-5-yl 2,4-dihydroxy-6-methylbenzoate

7-hydroxy-2-(2-hydroxyethyl)-6-(3-methylbut-2-en-1-yl)-3-oxo-1h-isoindol-5-yl 2,4-dihydroxy-6-methylbenzoate

C23H25NO7 (427.1631)


   

(6s,7r,8r)-6-hydroxy-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-yl acetate

(6s,7r,8r)-6-hydroxy-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-yl acetate

C23H25NO7 (427.1631)


   

6-hydroxy-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-yl acetate

6-hydroxy-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-yl acetate

C23H25NO7 (427.1631)